UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The American heart journal, ISSN 0002-8703, 2015, Volume 173, pp. 94 - 101
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Proprotein Convertases - antagonists & inhibitors | United States - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Incidence | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Cholesterol, VLDL - drug effects | Injections, Subcutaneous | Lipoproteins, LDL - drug effects | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Female | Serine Endopeptidases | Drug Therapy, Combination | Survival Rate - trends | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Risk Factors | Treatment Outcome | Cholesterol, VLDL - blood | Australia - epidemiology | Antibodies, Monoclonal - administration & dosage | Norway - epidemiology | United Kingdom - epidemiology | Lipoproteins, LDL - blood | Proprotein Convertase 9 | Monoclonal antibodies | Blood circulation disorders | Low density lipoproteins | Risk factors | Vascular diseases | Clinical trials | Cardiovascular disease | Lipids | Cardiovascular diseases | Low density lipoprotein | Statins | Morbidity | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2014, Volume 63, Issue 13, pp. 1278 - 1288
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2013, Volume 61, Issue 25, pp. 2495 - 2502
adverse drug event(s) | P-glycoprotein | drug-drug interaction | pharmacology | adverse drug event(s) drug-drug interaction P-glycoprotein pharmacology | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Protein Structure, Tertiary | Cardiovascular Agents - therapeutic use | Animals | Cardiovascular Diseases - metabolism | Cardiovascular Diseases - drug therapy | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Cardiovascular Agents - metabolism | Protein Transport - physiology | ATP-Binding Cassette, Sub-Family B, Member 1 - chemistry | Protein Transport - drug effects | Cardiovascular Agents - pharmacology | Anticoagulants | Membranes | Blood-brain barrier | Human immunodeficiency virus--HIV | Rodents | Nervous system | Permeability | Drug therapy | Binding sites | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
The American heart journal, ISSN 0002-8703, 2008, Volume 156, Issue 5, pp. 826 - 832
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Heart | Biological and medical sciences | Myocarditis. Cardiomyopathies | Medical sciences | Coronary heart disease | Acute Coronary Syndrome - drug therapy | Simvastatin - therapeutic use | Multicenter Studies as Topic | Azetidines - therapeutic use | Double-Blind Method | Simvastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Humans | Treatment Outcome | Ezetimibe, Simvastatin Drug Combination | Drug Combinations | Care and treatment | Cardiac patients | Patient outcomes | Simvastatin | Low density lipoproteins | Clinical trials | Comparative analysis | Cholesterol | Heart attacks | Acute coronary syndromes | Drug therapy | Index Medicus | Abridged Index Medicus | MEDICIN OCH HÄLSOVETENSKAP | MEDICAL AND HEALTH SCIENCES
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2016, Volume 67, Issue 24, pp. 2888 - 2899
dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2017, Volume 69, Issue 8, pp. 911 - 921
simvastatin | acute coronary syndrome | risk stratification | secondary prevention | ezetimibe | low-density lipoprotein cholesterol | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Simvastatin - therapeutic use | Prospective Studies | Risk Assessment | Humans | Middle Aged | Male | Treatment Outcome | Secondary Prevention | Acute Coronary Syndrome - complications | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Acute Coronary Syndrome - therapy | Female | Aged | Ezetimibe - therapeutic use | Myocardial Infarction - prevention & control | Hypertension | Heart failure | Stroke | Heart attacks | Cardiovascular disease | Lipids | Angina pectoris | Low density lipoprotein | Patients | Cholesterol | Disease prevention | Coronary vessels | Electrocardiography | Population | Diabetes | Kidney diseases | Health risk assessment | Acute coronary syndromes | Statins | Age
Journal Article
The American heart journal, ISSN 0002-8703, 2014, Volume 168, Issue 2, pp. 205 - 212.e1
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Simvastatin - therapeutic use | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Ezetimibe | Cholesterol, LDL - drug effects | Male | Azetidines - pharmacology | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Anticholesteremic Agents - pharmacology | Medical research | Low density lipoproteins | Simvastatin | Cardiac patients | Medicine, Experimental | Coronary heart disease | Antilipemic agents | Heart attacks | Acute coronary syndromes | Drug therapy | Cholesterol | Statins | Index Medicus | Abridged Index Medicus
Journal Article
8.
Full Text
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGEÂ AF-TIMI 48 Trial
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2017, Volume 69, Issue 11, pp. 1372 - 1382
NOACs | valvular heart disease | atrial fibrillation | edoxaban | anticoagulation | warfarin | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Humans | Middle Aged | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Male | Thiazoles - therapeutic use | Warfarin - therapeutic use | Heart Valve Diseases - complications | Aged, 80 and over | Female | Aged | Hemorrhage - chemically induced | Pyridines - therapeutic use | Myocardial infarction | Cardiac arrhythmia | Stenosis | Cardiovascular disease | Antagonists | Bleeding | Confidence intervals | Fibrillation | Surgery | Regurgitation | Aorta | Rheumatic heart disease | Safety | Heart diseases | Vitamin K | Anticoagulants | Cerebral infarction | Stroke | Warfarin | Echocardiography | Effectiveness | Health risks | Hazards | Patients | Thrombolysis | Coronary artery disease | Heart valves | Infarction | Cardiovascular diseases
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2015, Volume 65, Issue 24, pp. 2638 - 2651
cholesterol | lipids | low-density lipoprotein | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Proprotein Convertases - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Cardiovascular Diseases - drug therapy | Humans | Proprotein Convertases - metabolism | Enzyme Inhibitors - pharmacology | Antibodies, Monoclonal - therapeutic use | Cardiovascular Diseases - enzymology | Enzyme Inhibitors - therapeutic use | Animals | Clinical Trials as Topic - trends | Serine Endopeptidases - metabolism | Clinical Trials as Topic - methods | Cardiology - trends | Cardiology - methods | Cardiovascular Diseases - diagnosis | Proprotein Convertase 9 | Studies | Mutation | Low density lipoprotein | Cholesterol | Statins | Index Medicus | Abridged Index Medicus
Journal Article